Latest News
News Functions
Additional Functions
1 December 2021
Newron Pharmaceuticals SpA
Change in Newron Board of Directors
18 October 2021
Newron Pharmaceuticals SpA
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)
16 September 2021
Newron Pharmaceuticals SpA
Newron announces Half-Year 2021 results
Newron Pharmaceuticals SpA
Newron announces Half-Year 2021 results
Newron Pharmaceuticals SpA
Newron berichtet über Halbjahresergebnis 2021
6 September 2021
Newron Pharmaceuticals SpA
Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
Newron Pharmaceuticals SpA
Newron erhält vierte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
Newron Pharmaceuticals SpA
Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
Newron Pharmaceuticals SpA
Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia
Newron Pharmaceuticals SpA
Newron initiiert erste potenziell zulassungsrelevante Studie mit Evenamide bei Patienten mit Schizophrenie
Newron Pharmaceuticals SpA
Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia
20 May 2021
Newron Pharmaceuticals SpA
Newron announces Paragraph IV ANDA filings for Xadago® (safinamide) in the USA
Newron Pharmaceuticals SpA
Newron informiert über Einreichung weiterer Paragraph-IV-ANDA-Anträge für Xadago(R) (Safinamide) in den USA
Newron Pharmaceuticals SpA
Newron announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA
4 May 2021
Newron Pharmaceuticals SpA
Newron announces Paragraph IV ANDA filing for Xadago® (safinamide) in the USA
Newron Pharmaceuticals SpA
Newron informiert über Einreichung eines Paragraph-IV-ANDA-Antrages für Xadago(R) (Safinamide) in den USA
Newron Pharmaceuticals SpA
Newron announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA
13 April 2021
Newron Pharmaceuticals SpA
Newron announces AGM 2021 result
Newron Pharmaceuticals SpA
Newron announces AGM 2021 result
1 April 2021
Newron Pharmaceuticals SpA
Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
Newron Pharmaceuticals SpA
Newron gibt Ergebnisse der untersuchenden Studien mit Evenamide mit gesunden Probanden und Schizophrenie-Patienten bekannt
Newron Pharmaceuticals SpA
Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
16 March 2021
Newron Pharmaceuticals SpA
Newron gibt Geschäftsergebnisse 2020 und Ausblick 2021 bekannt
Newron Pharmaceuticals SpA
Newron announces 2020 financial results and provides outlook for 2021
15 March 2021
Newron Pharmaceuticals SpA
Newron und Zambon unterzeichnen Vereinbarung für potenziell zulassungsrelevante Studie mit Safinamide bei Parkinson-Patienten
Newron Pharmaceuticals SpA
Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson’s disease patients
21 January 2021
Newron Pharmaceuticals SpA
Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients
29 November 2020
Newron Pharmaceuticals SpA
DGAP-DD: Newron Pharmaceuticals S.p.A. english
15 September 2020
Newron Pharmaceuticals SpA
Newron berichtet über das Halbjahresergebnis 2020
Newron Pharmaceuticals SpA
Newron announces half-year 2020 results